Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials

BACKGROUND: The combined therapy of bevacizumab (BEV) with taxane (paclitaxel or docetaxel) has shown an improvement on progression-free survival (PFS) and objective remission in Her2-negative patients with locally recurrent or metastatic breast cancer (LR/MBC). However, there was no benefit in over...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaoqun, Liu, Xiangdong, Qiao, Tiankui, Chen, Wei, Yuan, Sujuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938144/
https://www.ncbi.nlm.nih.gov/pubmed/27445484
http://dx.doi.org/10.2147/OTT.S103954

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938144/
https://www.ncbi.nlm.nih.gov/pubmed/27445484
http://dx.doi.org/10.2147/OTT.S103954

Ejemplares similares